Evommune (EVMN) Invested Capital (2024 - 2026)

Evommune (EVMN) has 3 years of Invested Capital data on file, last reported at $304.6 million in Q1 2026.

• Quarterly Invested Capital rose 292.47% year-over-year to $304.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $304.6 million (up 292.47% YoY) and the FY2025 annual result came in at $205.6 million, up 242.52% from the prior year.
• Invested Capital rose to $304.6 million in Q1 2026 per EVMN's latest filing, from $205.6 million in the prior quarter.
• Across five years, Invested Capital topped out at $304.6 million in Q1 2026 and bottomed at -$183.1 million in Q3 2025.
• The 3-year median for Invested Capital is -$133.4 million (2024), against an average of -$16.3 million.
• The widest annual swing landed in 2025, when Invested Capital slumped 49.47%; it then surged 292.47% in 2026.
• Tracing EVMN's Invested Capital over 3 years: stood at -$144.2 million in 2024, then surged by 242.52% to $205.6 million in 2025, then soared by 48.15% to $304.6 million in 2026.
• Per Business Quant, the three latest EVMN Invested Capital figures stand at $304.6 million (Q1 2026), $205.6 million (Q4 2025), and -$183.1 million (Q3 2025).

Peer Comparison